Financial Performance - For the year ending December 31, 2025, the total comprehensive loss was RMB 305,972,000, a decrease of 21.1% from RMB 387,928,000 in 2024[3] - The company reported no revenue for the year 2025, compared to RMB 107,000 in 2024[5] - The group reported a loss before tax of RMB 305,972,000 for 2025, an improvement from a loss of RMB 387,928,000 in 2024, indicating a reduction in losses of about 21.1%[28] - The company's annual loss decreased by 21.1% from RMB 387.9 million in 2024 to RMB 306.0 million in 2025[83] - Basic and diluted loss per share improved to RMB 0.80 from RMB 1.15 in 2024[5] - The basic loss per share attributable to ordinary shareholders of the parent company for 2025 is RMB (0.80), compared to RMB (1.15) for 2024, indicating an improvement in performance[33] Research and Development - Research and development costs increased to RMB 244,064,000, up 3.7% from RMB 235,446,000 in 2024[3] - Research and development expenses for 2025 amounted to RMB 183,295,000, up from RMB 170,353,000 in 2024, reflecting an increase of approximately 7.6%[25] - R&D costs for the year ending December 31, 2025, amounted to RMB 244.1 million, a 3.7% increase from RMB 235.4 million in 2024, primarily due to milestone payments for TY-9591[77] - The R&D team consists of 117 members, with approximately 60% holding master's or doctoral degrees, covering all aspects of drug development[74] - The company has established a pipeline of 10 candidate drugs since its inception in 2017, including five clinical-stage products and four in early clinical development[52] Clinical Trials and Product Development - The core product TY-9591 has completed enrollment of 224 patients for its Phase II clinical trial for EGFR mutation lung cancer brain metastases, with a New Drug Application (NDA) submission expected in Q4 2025[44] - The company is conducting a Phase III clinical trial for TY-9591, with 541 patients enrolled as of July 2025, and expects to complete enrollment by Q4 2026[44] - The company has initiated a Phase II clinical trial for TY-302 in breast cancer and received ethics approval for a Phase II trial in prostate cancer as of July 2025[45] - TY-9591 demonstrated a median progression-free survival (PFS) of 19.3 months in EGFR L858R mutation lung cancer patients, compared to 14.4 months for osimertinib[61] - The NDA for TY-9591 has been accepted by the CDE and included in priority review for NSCLC brain metastases[54] Financial Position - Total assets decreased to RMB 779,737,000 from RMB 1,105,613,000 in 2024, reflecting a significant reduction in cash and bank balances[6] - Current liabilities increased to RMB 307,773,000 from RMB 289,081,000 in 2024, indicating a rise in trade and other payables[6] - The net asset value decreased to RMB 286,610,000 from RMB 472,562,000 in 2024, showing a decline in equity[7] - The total non-current assets decreased from RMB 74,471,000 in 2024 to RMB 44,157,000 in 2025, primarily due to a reduction in long-term asset prepayments[37] - As of December 31, 2025, the company's borrowings amounted to RMB 134,115,000, down from RMB 144,175,000 as of December 31, 2024, with a debt-to-asset ratio of approximately 63.2%[88] Regulatory and Compliance - Hong Kong Financial Reporting Standard No. 18 introduces new presentation requirements for the income statement, categorizing all income and expenses into five categories: operating, investing, financing, income tax, and discontinued operations[14] - The new standards and amendments are effective for annual periods beginning on or after January 1, 2027, with retrospective application required[14] - The company is currently analyzing the impact of the new regulations on its financial statement presentation and disclosures[14] - The audit committee consists of two independent non-executive directors and one non-executive director, with Mr. Jiang Xiaolin as the chairman[113] Shareholder and Governance - The annual general meeting is scheduled for June 23, 2026, with the H-share register closing from June 17 to June 23, 2026[117][118] - Proposed amendments to the company's articles of association include compliance with the latest regulatory requirements and the addition of audit, nomination, and remuneration committee powers[120] - The company will provide various methods, including online and electronic communication, for shareholders to participate in meetings, ensuring their attendance is recognized[122] - The company is committed to adhering to corporate governance codes as per the listing rules[128] Cash Flow and Financing - The net cash used in operating activities for the year ended December 31, 2025, was RMB 215,768,000, primarily due to a pre-tax loss of RMB 305,972,000[84] - The net cash generated from financing activities was RMB 126,384,000, primarily from new bank loans of RMB 110,000,000 and net proceeds from placements of RMB 141,366,000[85] - The company's capital expenditure during the reporting period totaled approximately RMB 39,413,000, mainly for the purchase of properties, plants, and equipment[87] Market and Commercialization Strategy - The company is actively expanding its commercialization team to enhance brand promotion and market potential through various academic and industry collaborations[75] - The company plans to adopt a strategy combining external collaboration and self-construction for commercialization, initially partnering with experienced external partners to enhance market expansion and brand promotion[100] - The company aims to transition from collaborative efforts to a primarily self-operated commercialization model, enhancing its core operational capabilities[100]
同源康医药(02410) - 2025 - 年度业绩